FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010108166> ?p ?o ?g. }

• W2010108166 endingPage "525" @default.
• W2010108166 startingPage "517" @default.
• W2010108166 abstract "To determine the safety and efficacy of the novel combination of docetaxel, oxaliplatin, and bevacizumab as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube after initial debulking surgery.Eligible patients (stage IB-IV) were treated with 6 cycles of oxaliplatin (85 mg/m(2)), docetaxel (75 mg/m(2)), and bevacizumab (15 mg/kg) every 3 weeks, followed by single-agent bevacizumab 15 mg/kg every 3 weeks to complete one year of therapy. The primary endpoint was 12-month progression-free survival (PFS).A total of 132 patients (80 with measurable disease at baseline; 52 with non-measurable, evaluable disease at baseline) enrolled and received study treatment. At diagnosis, 76.5% of patients had stage III disease and 20% had stage IV. 62.9% were optimally cytoreduced. The most common grade 3/4 adverse events were neutropenia (42.4%), leukopenia (13.6%), hypertension (8.3%), fatigue (6.1%), and nausea (6.1%). One patient (0.8%) had a fatal gastrointestinal perforation. The best overall confirmed response rate (complete response+partial response [measurable disease subgroup]) was 58.6% (95% CI 49%, 67%). CA-125 response rates for the measurable and non-measurable disease subgroups were 83.0% and 81.5%, respectively. The 12-month PFS rate for the measurable disease subgroup was 65.7% (95% CI 53.4%, 76.7%); median PFS was 16.3 (95% CI 12.6, 19.6) months. Median overall survival was 47.3 (95% CI 34.1, upper limit not applicable) months.This novel treatment regimen may provide a promising therapeutic approach for women with ovarian, primary peritoneal, or fallopian tube carcinoma. No unanticipated safety concerns were identified." @default.
• W2010108166 created "2016-06-24" @default.
• W2010108166 creator A5002181160 @default.
• W2010108166 creator A5005911289 @default.
• W2010108166 creator A5008763534 @default.
• W2010108166 creator A5014611244 @default.
• W2010108166 creator A5016295064 @default.
• W2010108166 creator A5024186639 @default.
• W2010108166 creator A5030811708 @default.
• W2010108166 creator A5044583210 @default.
• W2010108166 creator A5044655732 @default.
• W2010108166 creator A5062151371 @default.
• W2010108166 creator A5064038197 @default.
• W2010108166 creator A5075566972 @default.
• W2010108166 date "2014-03-01" @default.
• W2010108166 modified "2023-10-04" @default.
• W2010108166 title "A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube" @default.
• W2010108166 cites W2018460727 @default.
• W2010108166 cites W2081263829 @default.
• W2010108166 cites W2096521047 @default.
• W2010108166 cites W2105651363 @default.
• W2010108166 cites W2107402595 @default.
• W2010108166 cites W2113122060 @default.
• W2010108166 cites W2128868545 @default.
• W2010108166 cites W2129949847 @default.
• W2010108166 cites W2130941707 @default.
• W2010108166 cites W2135947389 @default.
• W2010108166 cites W2137697121 @default.
• W2010108166 cites W2139248078 @default.
• W2010108166 cites W2144870194 @default.
• W2010108166 cites W2154885792 @default.
• W2010108166 cites W2157920585 @default.
• W2010108166 cites W2164168201 @default.
• W2010108166 cites W2165948908 @default.
• W2010108166 cites W2226490553 @default.
• W2010108166 cites W4293241248 @default.
• W2010108166 doi "https://doi.org/10.1016/j.ygyno.2014.01.035" @default.
• W2010108166 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5718618" @default.
• W2010108166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24476788" @default.
• W2010108166 hasPublicationYear "2014" @default.
• W2010108166 type Work @default.
• W2010108166 sameAs 2010108166 @default.
• W2010108166 citedByCount "22" @default.
• W2010108166 countsByYear W20101081662013 @default.
• W2010108166 countsByYear W20101081662014 @default.
• W2010108166 countsByYear W20101081662015 @default.
• W2010108166 countsByYear W20101081662016 @default.
• W2010108166 countsByYear W20101081662018 @default.
• W2010108166 countsByYear W20101081662019 @default.
• W2010108166 countsByYear W20101081662020 @default.
• W2010108166 countsByYear W20101081662021 @default.
• W2010108166 countsByYear W20101081662022 @default.
• W2010108166 countsByYear W20101081662023 @default.
• W2010108166 crossrefType "journal-article" @default.
• W2010108166 hasAuthorship W2010108166A5002181160 @default.
• W2010108166 hasAuthorship W2010108166A5005911289 @default.
• W2010108166 hasAuthorship W2010108166A5008763534 @default.
• W2010108166 hasAuthorship W2010108166A5014611244 @default.
• W2010108166 hasAuthorship W2010108166A5016295064 @default.
• W2010108166 hasAuthorship W2010108166A5024186639 @default.
• W2010108166 hasAuthorship W2010108166A5030811708 @default.
• W2010108166 hasAuthorship W2010108166A5044583210 @default.
• W2010108166 hasAuthorship W2010108166A5044655732 @default.
• W2010108166 hasAuthorship W2010108166A5062151371 @default.
• W2010108166 hasAuthorship W2010108166A5064038197 @default.
• W2010108166 hasAuthorship W2010108166A5075566972 @default.
• W2010108166 hasBestOaLocation W20101081662 @default.
• W2010108166 hasConcept C121608353 @default.
• W2010108166 hasConcept C126322002 @default.
• W2010108166 hasConcept C141071460 @default.
• W2010108166 hasConcept C168563851 @default.
• W2010108166 hasConcept C191897082 @default.
• W2010108166 hasConcept C192562407 @default.
• W2010108166 hasConcept C203092338 @default.
• W2010108166 hasConcept C2775883341 @default.
• W2010108166 hasConcept C2776694085 @default.
• W2010108166 hasConcept C2777063308 @default.
• W2010108166 hasConcept C2777802072 @default.
• W2010108166 hasConcept C2778456384 @default.
• W2010108166 hasConcept C2778527123 @default.
• W2010108166 hasConcept C2780427987 @default.
• W2010108166 hasConcept C2780873365 @default.
• W2010108166 hasConcept C2780962732 @default.
• W2010108166 hasConcept C2781100745 @default.
• W2010108166 hasConcept C2781190966 @default.
• W2010108166 hasConcept C2781413609 @default.
• W2010108166 hasConcept C31760486 @default.
• W2010108166 hasConcept C526805850 @default.
• W2010108166 hasConcept C71924100 @default.
• W2010108166 hasConcept C90924648 @default.
• W2010108166 hasConceptScore W2010108166C121608353 @default.
• W2010108166 hasConceptScore W2010108166C126322002 @default.
• W2010108166 hasConceptScore W2010108166C141071460 @default.
• W2010108166 hasConceptScore W2010108166C168563851 @default.
• W2010108166 hasConceptScore W2010108166C191897082 @default.
• W2010108166 hasConceptScore W2010108166C192562407 @default.
• W2010108166 hasConceptScore W2010108166C203092338 @default.
• W2010108166 hasConceptScore W2010108166C2775883341 @default.

• next